Clinical trials for "prostate cancer" OR "breast cancer"

The European Union Clinical Trials Register allows you to search for protocol and results information on:

interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC

clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
Clinical Trials Information System (CTIS).

The EU Clinical Trials Register currently displays 44393 clinical trials with a EudraCT protocol, of which 7405 are clinical trials conducted with subjects less than 18 years old. The register also displays information on 18700 older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).

Examples: Cancer AND drug name. Pneumonia AND sponsor name.
How to search [pdf]

Advanced Search:

Search tools

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Trials with a EudraCT protocol (596)
Paediatric studies in scope of Art45 of the Paediatric Regulation (0)

596 result(s) found for: "prostate cancer" OR "breast cancer". Displaying page 30 of 30.

EudraCT Number: 2021-000546-17

Sponsor Protocol Number: D8534C00001

Start Date*: 2021-07-28

Sponsor Name:AstraZeneca AB

Full Title: SERENA-6: A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor...

Medical condition: Estrogen Receptor-Positive, HER-2 negative Advanced Breast Cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	100000004864	10072737	Advanced breast cancer	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: HU (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) BG (Trial now transitioned) PT (Trial now transitioned) AT (Trial now transitioned) SK (Trial now transitioned) NO (Trial now transitioned) BE (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2021-001685-38

Sponsor Protocol Number: 2693-CL-0312

Start Date*: 2021-11-24

Sponsor Name:Astellas Pharma Global Development, Inc.

Full Title: A Phase 3b, Randomized, Double-blind, Placebo-controlled, 24-week Study to Assess the Efficacy and Safety of Fezolinetant in Menopausal Women Suffering from Moderate to Severe Vasomotor Symptoms (H...

Medical condition: Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated with Menopause

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.0	100000004866	10020407	Hot flashes	LLT

Population Age: Adults

Gender: Female

Trial protocol: CZ (Completed) ES (Ongoing) IT (Completed) HU (Completed) FI (Completed) NL (Completed) NO (Completed) DE (Completed) PL (Completed) DK (Completed) BE (Completed) SK (Prematurely Ended) BG (Prematurely Ended)

Trial results: View results

EudraCT Number: 2015-002552-27

Sponsor Protocol Number: B9991004

Start Date*: 2016-07-14

Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017

Full Title: A PHASE 1B/2 OPEN-LABEL STUDY TO EVALUATE SAFETY, CLINICAL ACTIVITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB* (MSB0010718C) IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WI...

Medical condition: Locally advanced or metastatic solid tumors [eg, non-small cell lung cancer (NSCLC), melanoma, and squamous cell carcinoma of the head and neck (SCCHN)] triple-negative breast cancer (TNBC), or col...

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	19.0	100000004864	10048683	Advanced cancer	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Completed) DE (Completed) GB (GB - no longer in EU/EEA) FR (Completed)

Trial results: View results

EudraCT Number: 2019-003618-15	Sponsor Protocol Number: 20321	Start Date*: 2020-06-25
Sponsor Name:Bayer Consumer Care AG
Full Title: An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer-sponsored studies
Medical condition: Cancer
Disease:
Population Age: Adults, Elderly		Gender: Male
Trial protocol: CZ (Trial now transitioned) PL (Trial now transitioned) SE (Trial now transitioned) GB (GB - no longer in EU/EEA) HU (Trial now transitioned) LT (Trial now transitioned) FI (Trial now transitioned) FR (Trial now transitioned) PT (Completed) DE (Trial now transitioned) LV (Trial now transitioned) BG (Trial now transitioned) AT (Completed) EE (Completed) SK (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) NL (Ongoing) RO (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2021-001009-56

Sponsor Protocol Number: MK-7684A-005

Start Date*: 2021-10-12

Sponsor Name:Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.

Full Title: A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Coformation of Vibostolimab (MK-7684) with Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants with Se...

Medical condition: Advanced solid tumors

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	100000004864	10065252	Solid tumor	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2014-003277-42

Sponsor Protocol Number: MCLA-128-CL01

Start Date*: 2015-01-13

Sponsor Name:Merus B.V.

Full Title: A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors

Medical condition: Solid Tumors

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	17.1	100000004864	10049280	Solid tumour	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Ongoing) NL (Ongoing) FR (Trial now transitioned) PT (Completed) NO (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2022-000122-21	Sponsor Protocol Number: NVL-655-01	Start Date*: 2022-07-08
Sponsor Name:Nuvalent, Inc.
Full Title: A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)
Medical condition: Advanced Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors with ALK rearrangement or activating ALK mutation.
Disease:
Population Age: Adolescents, Under 18, Adults, Elderly		Gender: Male, Female
Trial protocol: FR (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2019-002281-12

Sponsor Protocol Number: SJX-653-006

Start Date*: 2019-12-03

Sponsor Name:Sojournix, Inc.

Full Title: A phase 2, prospective, randomized, double-blind, placebo-controlled clinical study to assess the efficacy, safety, tolerability, and pharmacokinetics of SJX-653 in postmenopausal women with modera...

Medical condition: Treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	100000004872	10027311	Menopause flushing	LLT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: GB (GB - no longer in EU/EEA) PL (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) BE (Completed)

Trial results: View results

EudraCT Number: 2019-002113-19

Sponsor Protocol Number: 42756493CAN2002

Start Date*: 2019-10-31

Sponsor Name:Janssen-Cilag International NV

Full Title: A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations

Medical condition: Advanced solid tumors (other than Urothelial tumors), and FGFR gene alterations.

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	100000004864	10065143	Malignant solid tumour	LLT

Population Age: Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: GB (GB - no longer in EU/EEA) PL (Completed) FR (Completed) DE (Trial now transitioned) ES (Ongoing) BE (Completed) IT (Completed) Outside EU/EEA SE (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2013-000314-38

Sponsor Protocol Number: 1206-HNCG

Start Date*: 2014-07-28

Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)

Full Title: A randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expre...

Medical condition: Salivary gland cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10061934	Salivary gland cancer	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: BE (Completed) FR (Completed) NL (Completed) GB (GB - no longer in EU/EEA) HU (Completed) AT (Completed) GR (Completed) IT (Completed)

Trial results: (No results available)

EudraCT Number: 2020-002359-39

Sponsor Protocol Number: 213406

Start Date*: 2020-09-18

Sponsor Name:GlaxoSmithKline Research & Development Limited

Full Title: A PHASE 1, MULTICENTRE, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION STUDY OF NIRAPARIB AND DOSTARLIMAB IN PAEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMOURS

Medical condition: Recurrent or refractory solid tumour

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	100000004864	10065147	Malignant solid tumor	LLT
	21.1	100000004864	10065252	Solid tumor	LLT

Population Age: Infants and toddlers, Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2021-002326-24

Sponsor Protocol Number: ALKS4230-007

Start Date*: 2023-02-13

Sponsor Name:Mural Oncology, Inc.

Full Title: A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial O...

Medical condition: Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10033128	Ovarian cancer	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10016180	Fallopian tube cancer	PT
	20.1	10022891 - Investigations	10080244	Peritoneal cancer index	PT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: DE (Trial now transitioned) ES (Ongoing) PL (Prematurely Ended) IT (Trial now transitioned) NO (Trial now transitioned) AT (Trial now transitioned) LT (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2020-004554-30

Sponsor Protocol Number: LOXO-BTK-20020

Start Date*: 2021-06-04

Sponsor Name:Loxo Oncology Inc

Full Title: A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/...

Medical condition: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10008976	Chronic lymphocytic leukemia	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IE (Trial now transitioned) AT (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) HR (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2021-000043-49

Sponsor Protocol Number: LOXO-BTK-20022

Start Date*: 2021-08-16

Sponsor Name:Loxo Oncology Inc

Full Title: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Sm...

Medical condition: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.0	100000004864	10008976	Chronic lymphocytic leukemia	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) PL (Trial now transitioned) NO (Completed) HU (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2017-001111-36	Sponsor Protocol Number: CAN04CLIN001	Start Date*: 2018-01-25
Sponsor Name:Cantargia AB
Full Title: An open label, dose escalation followed by dose expansion, safety and tolerability trial of CAN04, a fully humanized monoclonal antibody against IL1RAP, in subjects with solid malignant tumors
Medical condition: Solid malignant tumors, in the following two indications; Non-Small Cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC),
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: BE (Completed) NO (Completed) DK (Completed) NL (Completed) DE (Completed) AT (Completed) SE (Completed) EE (Completed) ES (Ongoing) LT (Completed) LV (Completed)
Trial results: View results

EudraCT Number: 2015-000952-11

Sponsor Protocol Number: PR-30-5017-C

Start Date*: 2016-07-01

Sponsor Name:TESARO, Inc.

Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Base...

Medical condition: Homologous recombination deficiency advanced ovarian cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10033128	Ovarian cancer	PT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: FI (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) SE (Trial now transitioned) IE (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) HU (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)

Trial results: View results

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

For support, Contact us.

The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

European Medicines Agency © 1995-Sun Apr 05 03:14:52 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA